The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | VLS-101: an ADC for MCL and DLBCL
Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, discusses the preliminary results of a Phase I study (NCT03833180) of VLS-101, an antibody drug conjugate (ADC), targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in patients with previously treated B-cell malignancies. Thus far, the results have demonstrated good efficacy, particularly in patients with refractory mantle cell lymphoma (MCL) who have failed treatment with BTK inhibitors. Efficacy has also been demonstrated in patients with diffuse large B-cell lymphoma (DLBCL). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Jacqueline Barrientos, MD, MS, has received research funding from AstraZeneca, Oncternal, TG therapeutics and Pharmacyclics/Abbvie; and has participated in advisory boards for AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead and Innate.
